Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Hormones & cancer - 1 Feb 2015

Cabanillas M E, Patel A, Danysh B P, Dadu R, Kopetz S, Falchook G

Abstract excerpt

The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine-refractory BRAF-mutant papillary thyroid cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Disease Management
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25467940
DOI: 10.1007/s12672-014-0207-9
PMCID: PMC4312215

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.PMID 25467940Read ↗

Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success.Semantic proximity Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Clinical Development of BRAF plus MEK Inhibitor Combinations.Semantic proximity Read ↗

BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Semantic proximity Read ↗

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.Semantic proximity Read ↗

Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience.Semantic proximity Read ↗

Vemurafenib Active in Iodine-Refractory Thyroid Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.